

THE PRESENT STATUS OF OF BUERGER'S DISEASE: DOES IT STILL EXIST: HOW TO DIAGNOSE AND TREAT IT

Kamphol Laohapensang, MD, FACS
 Professor Emeritus of Vascular Surgery,
 Department of Surgery,
 Chiang Mai University Hospital,
 Chiang Mai, 50100
 Thailand
 Email: klaohape@gmail.com



VEITH 93 Laohapensang 11-22-24 2:48 P.



DISCLOSURES
 I HAVE NOTHING
 TO DISCLOSE

BUERGER'S DISEASE

Non-atherosclerotic, inflammatory, segmental occlusive disease of unknown origin affecting the medium and small arteries and veins of young male

Tobacco use has a strong link to the pathogenesis and progression

Enderteritis introduced by T-cells and B-cells mediated immunity with the activation of macrophages in intima

DIAGNOSTIC CRITERIA OF SHIONOYA

- Smoking history
- Onset before the age of 50 years
- Infra-popliteal and infra-brachial arterial occlusions
- Either arm involvement or phlebitis migrans
- Absence of atherosclerotic risk factors other than smoking


Shionoya S: Diagnostic Criteria of Buerger's disease. Int J Cardiol 1998;1: 243-5.



DIAGNOSTIC CRITERIA OF SHIONOYA

- **Special arteriographic findings:** abrupt or tapering occlusion, cockscrew collaterals, and absence of calcification or moth-eaten stenoses
- **Exclusion criteria:** patients with hypertension, diabetes mellitus, hyperlipidemia, ischemic heart disease, cerebrovascular disease, hypercoagulable state or collagen disease

Shionoya S: Diagnostic Criteria of Buerger's disease. Int J Cardiol 1998;1: 243-5.

PAN-ARTERITIS OF TAO






THE OVERALL INCIDENCE OF TAO APPEARS TO BE DECREASING DUE TO

- Adoption of precise diagnostic criteria [Shionoya, Olin, Adar, Papa etc.]
- Reduction of smoking population [Younger generation]
- Change in the occupations [Agriculture to Industrialization]

1. Laohapensang K, Rerkasem K, Kittipattanaong V: Buerger's disease in northern Thailand, *Surg Today* 2005; 35:1060-1065.
2. Matsushita M, Nishikimi N, Sakurai T, et al: Decrease in prevalence of Buerger's disease in Japan, *Surgery* 1998; 124:498-502.



DOES BERGER'S DISEASE REALLY EXIST:

YES, but DECREASING

THE CURRENT BEST TREATMENT:

Cessation of smoking

ORIGINAL RESEARCH

Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients

Jesús Rivera, MD, PhD, Daniel Suárez, MD, Juanjo Suárez, MD, César Espiña, MD, Fabian Casas, MD, Felipe Claret, MD, Renee Yusef Hatan, MD, Joseph Formanek, MD, Patricia Casado, MD, Mateo Reuche-Rigon, MD, Marc Lambert, MD, PhD, David Saez, MD, PhD, for the French Buerger's Network

Background—Data regarding long-term outcome of patients with thromboangiitis obliterans are lacking and most series come from India and Japan. In this study, we assess long-term outcome and prognostic factors in a large cohort of thromboangiitis obliterans.

Methods and Results—Retrospective multicenter study of characteristics and outcomes of 224 thromboangiitis obliterans patients fulfilling Papanicolaou's criteria were analyzed. Factors associated with vascular events and amputations were identified. The median age at diagnosis was 38.3 (20–66) years, 51 (22.8%) patients were female, and 81.7% were white. After a mean follow-up of 5.7 years, vascular events were observed in 58.9%, amputations in 21.4%, and death in 1.4%. The 5-, 10-, and 15-year vascular event-free survival and amputation-free survival were 41% and 59%, 28% and 74%, and 19% and 68%, respectively. Stroke prior to enrollment (hazard ratio 2.25 [1.30–4.27], $P < 0.005$) and limb infection at diagnosis (hazard ratio 3.29 [1.21–10.4], $P = 0.045$) were independent factors of vascular event-free survival. Factors associated with amputation were limb infection (hazard ratio 12.1 [3.5–42.5], $P < 0.001$). Patients who stopped that tobacco consumption had lower risk of amputation ($P = 0.051$) than those who continued.

Conclusions—This nationwide study shows that 58% of thromboangiitis obliterans patients will experience an amputation within 15 years from diagnosis. We identified high-risk patients for vascular complications and amputations. (*J Am Heart Assoc.* 2018;7:e018177. DOI: 10.1161/JAHA.118.018177).

Key Words: Buerger's disease • outcome • prognosis • thromboangiitis obliterans • vascular

FACTS ABOUT BUERGER'S DISEASE

Only 11.5% (9 / 78) of the patients stopped smoking

The risk of amputation is eliminated by 8 years after smoking cessation

Arterial reconstructions were feasible in 10.2% (11 / 78) of TAO cases

The necrotic lesions subsides after the age of 60

Laohapansang K, et al. Surg Today 2005; 35:1060-1065.

REVASCULARIZATION

- Revascularization is the ideal treatment to reduce ischemic injuries
- Surgical revascularization is often not feasible because of diseased distal runoff and diffuse segmental involvement and thrombotic nature of the disease
- Lack of distal targets for bypass and absence of adequate vein conduit
- Bypass surgery was carried out for less than 10% of surgically treated patients

1. Ye K, et al. Endovascular recanalization versus autogenous venous bypass for TAO patients. *J Vasc Surg* 2017; 46: 1133-1142.

2. Kim DH, et al. Immediate and late outcomes of endovascular treatment of Buerger's disease. *J Vasc Surg* 2018; 47: 1769-1777.


Surgical Treatment of Buerger's disease 1988-2002

Table 4. Surgical treatment of the 78 patients with Buerger's disease on 108 admissions

	Recurrent admission patients (n = 37)	New admission patients (n = 41)	Total admissions (n = 108)
Arterial reconstruction	4 (10.8%)	7 (17%)	11 (10.2%)
Sympathectomy	13 (35.1%)	23 (56%)	36 (33.3%)
Amputation			
Above knee	1 (2.7%)	—	1 (0.9%)
Below knee	3 (8.1%)	1 (2.4%)	4 (3.6%)
Syme's	2 (5.4%)	1 (2.4%)	3 (2.7%)
Transmetatarsal	2 (5.4%)	1 (2.4%)	3 (2.7%)
Digital	33 (89.2%)	34 (82.9%)	67 (62%)

Some patients underwent more than one operation





Laohapansang K, Surg Today 2005; 35(15): 410-20.



FEMORO-PERONEAL BYPASS



AUTOGENOUS VEIN HARVESTING



Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease

Dae-Hoon Kim, MD¹, Young-Cuk Koo, MD², Chul-Min Ahn, MD, PhD³, Dong-In Shin, MD, MPH⁴, Jung-Sun Kim, MD, PhD⁵, Byoung-Hwa Kim, MD, PhD⁶, Donghoon Choi, MD, PhD⁷, Myoung-Ki Hong, MD, PhD⁸, and Yangsoo Jung, MD, PhD⁹, Seoul, Korea

ABSTRACT

Objective: Buerger disease is a rare inflammatory vasculopathy presenting with severe claudication or critical limb ischemia. In this study, we sought to evaluate the feasibility and clinical outcomes of endovascular therapy for Buerger disease involving arteries in the lower extremities.

Methods: Between January 2005 and May 2006, there were 46 Buerger disease patients (83 men; mean age, 42.4 ± 9.8 years) with 50 target limbs treated by endovascular therapy at the Severance Cardiovascular Hospital. Baseline characteristics as well as both immediate and late clinical outcomes were retrospectively analyzed.

Results: The majority (98.4%) of patients presented with critical limb ischemia. A total of 88 target lesions in 50 limbs were treated with endovascular procedures. All limbs showed antithrombotic artery occlusion, and multilevel disease involving the iliac or femoropopliteal artery were found in 21 patients (45%). Technical success was achieved in 80% of subjects, the limb that shows severe level of disease prior to therapy. The long-term primary and secondary limb salvage rates were 63.3% and 67.9%, respectively. In a multivariate Cox proportional hazards analysis, previous endovascular treatment (hazard ratio, 1.76; 95% CI, 1.20-2.51, P = .002) and previous amputation (hazard ratio, 4.66; 95% CI, 1.37-15.98, P = .014) were identified as independent risk factors for reintervention and amputation-free survival.

Conclusions: In patients with Buerger disease, endovascular treatment achieved technical success in the majority of the cases and was associated with favorable immediate and late clinical outcomes. These findings indicate that endovascular therapy may be considered a first-line treatment option for severe symptomatic patients with Buerger disease. (J Vasc Med Biol 2017; 29:1)

DO BYPASSES OR ENDO TREATMENTS WORK

- Surgical revascularization is not feasible 90% due to the lack of venous conduit and distal arterial targets for bypass
- Endovascular treatment should be considered

1. Galanos G, et al. A SYSTEMATIC REVIEW AND META-ANALYSIS OF EARLY AND LATE OUTCOMES AFTER ENDOVASCULAR ANGIOPLASTY AMONG PATIENTS WITH THROMBOANGIITIS OBLITERANS AND CHRONIC LIMB ISCHEMIA. JVS. September 25, 2022.
2. Ye K, et al. Endovascular recanalization versus autogenous venous bypass for TAO patients. J Vasc Surg 2017; 66: 1133-1142.

ENDOVASCULAR TREATMENT FOR BUERGER'S DISEASE PATIENT

Majority of patients with CLI are poor candidates for surgical bypass, endovascular approaches should be considered

Percutaneous transluminal angioplasty (PTA) of infrapopliteal arteries and can be an effective option

Prolonged balloon inflation has been recommended for PTA

Selective stent placement can be considered for residual stenosis, vessel recoil, or dissection

Re-intervention is possible

VEITH Symposium NEWS 2022

How will AI change vascular medicine?

Buerger's disease is not a variant of atherosclerosis

Buerger's disease is a unique, non-atherosclerotic, non-inflammatory, segmental disease of unknown origin.

Prevalence of endovascular angioplasty use is consistently higher and potentially effective option for managing patients with Buerger's disease and CLI.

ASVS 2024

Quality Improvement in Vascular Surgery

Bangkok, Thailand

December 3-6, 2024

THANK YOU FOR ATTENTION